Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Prothena Corp PRTA in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 4 | 3 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 2 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $72.5, a high estimate of $129.00, and a low estimate of $35.00. Observing a downward trend, the current average is 6.88% lower than the prior average price target of $77.86.
Exploring Analyst Ratings: An In-Depth Overview
An in-depth analysis of recent analyst actions unveils how financial experts perceive Prothena Corp. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $90.00 | $90.00 |
| Jay Olson | Oppenheimer | Lowers | Outperform | $80.00 | $98.00 |
| Jason Butler | JMP Securities | Raises | Market Outperform | $85.00 | $81.00 |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $35.00 | $36.00 |
| Tazeen Ahmad | B of A Securities | Lowers | Neutral | $38.00 | $68.00 |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $36.00 | $43.00 |
| Charles Duncan | Cantor Fitzgerald | Lowers | Overweight | $87.00 | $129.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $129.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Prothena Corp. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Prothena Corp compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Prothena Corp's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Prothena Corp's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Prothena Corp analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Unveiling the Story Behind Prothena Corp
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Prothena Corp: Financial Performance Dissected
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining Prothena Corp's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -99.37% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Prothena Corp's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -21353.16%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Prothena Corp's ROE stands out, surpassing industry averages. With an impressive ROE of -11.45%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Prothena Corp's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -9.35%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Prothena Corp's debt-to-equity ratio is below the industry average at 0.02, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Basics of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
